Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Psilocybin-assisted psychotherapy for cognitive impairment in treatment-resistant depression
EF 2024-25
Résumé
Background: Depression affects millions of people around the world. In addition to mood-related symptoms, such as increased sadness, 30-50% of people with depression will also experience cognitive impairment (e.g., problems with memory, attention, and language). Cognitive impairment is linked to more severe symptoms, reduced recovery rates, and higher economic burden. Unfortunately, traditional depression treatments mainly target mood symptoms, leaving many individuals struggling with lingering cognitive challenges even after their mood improves. Recently, psilocybin, the active compound in "magic mushrooms," has been shown to relieve the mood symptoms of depression when combined with talk therapy ("psilocybin-assisted therapy"). However, its effects on cognition have not been explored.
Objective: Our study will be the first to investigate the short- and long-term effects of psilocybin-assisted therapy on cognitive function in adults with difficult-to-treat depression.
Methods: In this study, 46 participants will receive one low dose (placebo, 1 mg) and one high dose (25 mg) of psilocybin, while another group of 46 participants will receive two high doses of psilocybin. We will measure cognitive functioning before participants receive the first dose of psilocybin, two weeks after each dose, and three and six months after the last dose.
Anticipated Results: We expect that one 25 mg dose of psilocybin will improve cognitive function more than the 1 mg placebo. We also expect that receiving two 25 mg doses will lead to even greater improvements in cognitive function.
Significance: This will be the first study to assess whether psilocybin can reduce cognitive impairment in people with difficult-to-treat depression. Our findings will help enhance our understanding of cognitive impairment and potentially change how depression is treated. They may also pave the way for new research on treating cognitive impairments in other physical and mental health conditions.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518385
Name
Johnson Danica E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Psilocybin-assisted psychotherapy for cognitive impairment in treatment-resistant depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Clinical Neuroscience; Cognitive Impairment; Neuropsychology; Psilocybin-Assisted Psychotherapy; Randomized Controlled Trial; Treatment-Resistant Depression
Abstract
Background: Depression affects millions of people around the world. In addition to mood-related symptoms, such as increased sadness, 30-50% of people with depression will also experience cognitive impairment (e.g., problems with memory, attention, and language). Cognitive impairment is linked to more severe symptoms, reduced recovery rates, and higher economic burden. Unfortunately, traditional depression treatments mainly target mood symptoms, leaving many individuals struggling with lingering cognitive challenges even after their mood improves. Recently, psilocybin, the active compound in "magic mushrooms," has been shown to relieve the mood symptoms of depression when combined with talk therapy ("psilocybin-assisted therapy"). However, its effects on cognition have not been explored.
Objective: Our study will be the first to investigate the short- and long-term effects of psilocybin-assisted therapy on cognitive function in adults with difficult-to-treat depression.
Methods: In this study, 46 participants will receive one low dose (placebo, 1 mg) and one high dose (25 mg) of psilocybin, while another group of 46 participants will receive two high doses of psilocybin. We will measure cognitive functioning before participants receive the first dose of psilocybin, two weeks after each dose, and three and six months after the last dose.
Anticipated Results: We expect that one 25 mg dose of psilocybin will improve cognitive function more than the 1 mg placebo. We also expect that receiving two 25 mg doses will lead to even greater improvements in cognitive function.
Significance: This will be the first study to assess whether psilocybin can reduce cognitive impairment in people with difficult-to-treat depression. Our findings will help enhance our understanding of cognitive impairment and potentially change how depression is treated. They may also pave the way for new research on treating cognitive impairments in other physical and mental health conditions.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Johnson, Danica E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~